The antibody was originally discovered by isolating antibodies from individuals exposed to S.aureus using Symphogen’s patented Symplex technology.
Commenting on the announcement, Chief Executive Officer of Symphogen, Martin Olin, said: “Genentech’s decision to move this exciting new investigational medicine forward is an important advancement for Symphogen’s technology platform which underpins our antibody discovery and development work. S. aureus is recognized by the WHO and CDC as one of the most important resistant bacteria for which there is a serious need for new treatments. This represents an important step forward in addressing the unmet need associated with serious S. aureus infections, potentially improving outcomes for patients with the disease.”
For additional information, please contact:
Martin Olin, Chief Executive Officer
Phone: +45 40 21 85 32
Consilium Strategic Communications
Phone: +44 20 3709 5700